Kevin Grogan

Kevin Grogan

Managing Editor

London, UK

Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Latest from Kevin Grogan

Plaudits For MeiraGTx And Its Parkinson’s AI Pact

A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.

Zealand Turnaround Complete In Three Years

CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.

Roche Means Business With Biggest Ever Obesity Pact

The Swiss giant has inked a deal potentially worth $5.30bn with Zealand to access the Danish biotech's long-acting amylin analog petrelintide.

What’s Hot And What’s Not For Sofinnova

Chairman Antoine Papiernik spoke to Scrip about the therapeutic areas that where the VC major is looking at to invest its considerable cash pile.

J&J Dreams Of ICONIC Status For Icotrokinra

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

Merck KGaA Talks More Deals But Stays Silent On SpringWorks

The late-stage cupboard is looking bare but the German firm has its eyes on products with peak sales potential of over €500m.